A strategic agreement has been announced that will see all shares of Cytena be sold to Cellink for a purchase price of EUR30.25 million (US$33.79 million).
A strategic agreement has been announced that will see all shares of Cytena, a life-sciences company focused on single-cell technologies, be sold to Cellink, a 3D bioprinter specialist, for a purchase price of EUR30.25 million (US$33.79 million).
The reasoning for the strategic acquisition has been specified as being synergy between the companies, which is anticipated to enable market opportunities, and a desire by Cellink to expand into the pharmaceutical space.
“In Cellink, we have found a great partner, which shares our vision for the company and will help us to further accelerate Cytena’s growth,” said Jonas Schoendube, CEO, Cytena in an Aug. 5, 2019 press release. “We see interesting synergies in marketing, sales, and R&D between all four group member companies […] Our customers and partners will benefit from an extended product offering and a stronger global presence.”
“We are excited to welcome Cytena to the Cellink family of life-science companies with this strategic acquisition,” added Erik Gatenholm, CEO, Cellink. “We are furthering CELLINK's global commercial strategy by focusing on the pharmaceutical industry […] With Cytena’s technology platforms, we will streamline workflows for our present and future customers, and enhance our presence in the pharmaceutical industry, a strategy that is well aligned with our vision. Together with Dispendix, we will be well-positioned to offer comprehensive solutions for both academic and pharmaceutical customers worldwide.”
The management of Cytena and its entity will remain the same after the acquisition is completed.